Clinical relevance and concordance of HER2 status in local and central testing-an analysis of 1581 HER2-positive breast carcinomas over 12 years.

about

Clinical relevance and concordance of HER2 status in local and central testing-an analysis of 1581 HER2-positive breast carcinomas over 12 years.

Item

http://www.wikidata.org/entity/Q47260496

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Clinical relevance and concord ...... east carcinomas over 12 years.

@en

Clinical relevance and concord ...... east carcinomas over 12 years.

@nl

type

Item

label

Clinical relevance and concord ...... east carcinomas over 12 years.

@en

Clinical relevance and concord ...... east carcinomas over 12 years.

@nl

prefLabel

Clinical relevance and concord ...... east carcinomas over 12 years.

@en

Clinical relevance and concord ...... east carcinomas over 12 years.

@nl

P1476

Clinical relevance and concord ...... east carcinomas over 12 years.

@en

P2093

Agnes Bankfalvi

http://www.w3.org/2001/XMLSchema#string

Berit M Pfitzner

http://www.w3.org/2001/XMLSchema#string

Bianca Lederer

http://www.w3.org/2001/XMLSchema#string

Bruno V Sinn

http://www.w3.org/2001/XMLSchema#string

Carsten Denkert

http://www.w3.org/2001/XMLSchema#string

Christine Solbach

http://www.w3.org/2001/XMLSchema#string

Christoph Salat

http://www.w3.org/2001/XMLSchema#string

Gunter von Minckwitz

http://www.w3.org/2001/XMLSchema#string

Hans Tesch

http://www.w3.org/2001/XMLSchema#string

Judith Lindner

http://www.w3.org/2001/XMLSchema#string

P2860

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC) ± bevacizumab - results of the randomised GeparQuinto study (GBG 44).

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.

Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study.

Automated extraction of DNA and RNA from a single formalin-fixed paraffin-embedded tissue section for analysis of both single-nucleotide polymorphisms and mRNA expression.

Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancer

Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience.

Quality assessment of HER2 testing by monitoring of positivity rates

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

P2888

modpathol.2017.171

P31

scholarly article

P356

10.1038/MODPATHOL.2017.171

http://www.w3.org/2001/XMLSchema#string

P50

Andreas Schneeweiss

Sibylle Loibl

P577

2017-12-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29271415

http://www.w3.org/2001/XMLSchema#string